[ad_1]
In a statement, Moderna reveals that the final results of the Covid-19 vaccine tests show a 94.1 percent effectiveness, with an efficiency reaching 100 percent when dealing with severe cases.
The tests in question included 196 participants with confirmed cases of Covid-19, including 30 severe cases.
The pharmaceutical company adds that “the vaccine’s efficacy was consistent with respect to age, race, ethnicity and sex.”
The 196 cases included older adults (over 65) and “42 participants who identified themselves as belonging to different communities”.
Adds that the vaccine “remains generally well tolerated, with no record of cases with severe effects identified to date “.
Emergency authorization
With these results, Moderna will still apply for emergency clearance from the Food and Drug Administration (FDA) in the United States today. The American pharmaceutical company expects the results of these tests to be considered during the meeting of the Advisory Committee on Vaccines and Related Biological Products (VRBPAC), which will be held on December 17.
Similarly, an emergency authorization will still be requested from the European Medicines Agency (EMA) today.. In the next few days Moderna intends to proceed with the registration procedure with the World Health Organization (WHO).
Despite rapid progress, this vaccine is expected to reach the North American market first. Moderna received $ 2.48 billion in federal funds from the United States as part of the Trump administration’s Operation Warp Spped.
This pharmaceutical company has already signed contracts in different parts of the world for the supply of the vaccine, but the United States alone is expected to have 20 million doses available by the end of 2020.
In August, the United States purchased a total of 100 million doses, with the option to purchase another 500 million. Moderna guarantees that it will produce between 500 million and 1 billion doses globally over the next year.
This is the third vaccine to pass the last phase of testing after the results revealed by Pfizer and AstaZeneca / Oxford University. It is known for now that the Pfizer vaccine requires very low temperatures to be stored (in the range from -70 to -80 ° C), while the Moderna vaccine tolerates less demanding temperatures, but has a very high cost, limiting its universality.
The British University of Oxford vaccine is less effective – 70 percent – but is more affordable in terms of price and doesn’t require such low temperatures.
.
[ad_2]
Source link
